FDA Brief

Warning letters Biologics

FDA warning letter to

Green Valley Fertility Partners

High riskIssued Dec 3, 2025Posted Dec 16, 2025Center for Biologics Evaluation and Research (CBER)

FDA cited Green Valley Fertility Partners for donor eligibility failures involving oocyte HCT/Ps, including missing communicable disease testing and screening.

What happened

During an inspection between May 8, 2025, and May 14, 2025, FDA documented violations of HCT/P donor eligibility rules at Green Valley Fertility Partners in Henderson, NV. FDA found oocytes recovered without West Nile Virus nucleic acid test (NAT) testing, an incomplete donor questionnaire, a donor with a risk factor determined eligible, eligibility decisions made before testing and exams were complete, and donor names or first names used on records. FDA said the West Nile Virus testing issue was a repeat violation.

What FDA found

  1. The firm did not test an oocyte donor for West Nile Virus with an FDA-licensed nucleic acid test, and FDA said this was a repeat violation.

    21 CFR 1271.85(a)
  2. The donor infectious disease questionnaire did not ask about all required risk factors and deferral periods, such as hepatitis contact, West Nile Virus diagnosis, CJD/vCJD, and certain European residence or military base residence.

    21 CFR 1271.75(a)(1)
  3. FDA found a directed oocyte donor who answered yes to living in Europe for 5 years or more but was still determined eligible.

    21 CFR 1271.75(d)
  4. The firm determined two oocyte donors eligible before receiving donor test results and/or completing physical exams and questionnaires.

    21 CFR 1271.50(a)
  5. The Summary of Records included anonymous oocyte donors' names and birthdates.

    21 CFR 1271.55(c)
  6. The firm identified anonymous oocyte donors as 'OD' plus first name instead of a distinct code that does not include personal information.

    21 CFR 1271.55(a)(1)

What FDA wants

FDA asks the firm to respond in writing within 15 working days with steps taken or planned, how it will prevent recurrence, and supporting documentation. It also says affected oocytes, semen, and embryos must stay in quarantine unless FDA grants an exemption or the embryos meet release labeling rules.

Who should pay attention

  • fertility clinics using donor oocytes
  • tissue banks and sperm banks
  • IVF patients and donors

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Central Coast Multispecialty Medical Group, Inc.

    FDA warns Central Coast Multispecialty Medical Group over incomplete donor screening and eligibility for reproductive tissue.

    High risk
  2. Conceive Fertility Center

    FDA says Conceive Fertility Center in Dallas used incomplete donor screening and testing for reproductive cells.

    High risk
  3. Louisville Reproductive Center

    Louisville Reproductive Center failed to properly test and screen semen donors for infectious diseases, FDA found.

    High risk
  4. Lux Therapeutics LLC dba Ponya Therapeutics LLC

    FDA warns Lux Therapeutics over unvalidated TheraMend amniotic patches and records, citing inadequate response and Luxegen distribution concerns.

    High risk